Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01161134
Recruitment Status : Completed
First Posted : July 13, 2010
Last Update Posted : July 13, 2010
Information provided by:
Dr. Reddy's Laboratories Limited

Brief Summary:
The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Boehringer Ingelheim Pharmaceuticals Inc., USA) under fasting conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Meloxicam Phase 1

Detailed Description:
Twenty eight (twenty six study subjects + two alternate subjects)healthy male and/or female subjects participated in an open label, two-period, two-sequence, two- treatment,single dose, two-way crossover study with at least 14 days washout between doses conducted under fasting conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparative Bioavailability Study of Meloxicam 15 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics) Vs. Mobic® 15 mg Tablets (Boehringer Ingelheim Pharmaceuticals Inc.,Usa) in Healthy Male And/Or Female Volunteers Under Fasting Conditions-P1cx04001
Study Start Date : September 2004
Actual Primary Completion Date : November 2004
Actual Study Completion Date : November 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Meloxicam

Arm Intervention/treatment
Experimental: Meloxicam
Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
Drug: Meloxicam
Meloxicam Tablets 15 mg
Other Name: Mobic Tablets 15 mg

Active Comparator: Mobic
Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
Drug: Meloxicam
Meloxicam Tablets 15 mg
Other Name: Mobic Tablets 15 mg

Primary Outcome Measures :
  1. Bioequivalence on Cmax and AUC parameters [ Time Frame: 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. The subject must be a healthy male or female volunteer.If the volunteer is female. she must demonstrate β-CG levels consistent with the nongravid state at the medical screening visit and at check-in for Period 1 and agree to remain abstinent or use double-barrier contraception (partner using condom and female volunteer using diaphragm, contraceptive sponge, spermicide, or IUD). If the female is post-menopausal or is surgically sterile, she is exempt from this requirement. (Postmenopausal is defined as no menses for the previous 1 year. If cessation of menses is within 18 months, FSH and/or LH must be documented prestudy as elevated into the postmenopausal range.).
  2. The subject must be between the ages of 18 - 55 years old (inclusive).
  3. The Subject's body mass index (BMI) must be within 19.0 - 30.0 (Kg/m2).
  4. The subject must be a non-smoker and not using any nicotine products.
  5. The subject must sign the written consent form (Research Subject Information and Consent Form) prior to study entry.
  6. The subject must have clinically acceptable results from the screening procedure including blood pressure, heart rate, ECG, physical exam, medical history, hematology, biochemistry, urinalysis. and infection screen (Hepatitis B Antigen, Hepatitis C Antibody, HIV)

Exclusion Criteria:

  1. Subjects with a history of clinically significant gastro-intestinal, dermatological, cardiovascular, renal, hematological, neurological, hepatic, pulmonary, or endocrine disease in the last 12 months.
  2. Subjects determined by the Investigator to have any medical condition which may affect the absorption, distribution, metabolism or excretion of the investigational product, or that could jeopardize their health or prejudice the results (e.g. history of surgery of the gastro-intestinal tract, except for appendectomy).
  3. Subjects with a known allergy to meloxicam (Mobic) or other nonsteroidal anti-inflammatory drugs (NSAIDS) [e.g. Motrin® (ibuprofen), Celebrex® (celecoxib). Vioxx® (rofecoxib). Naprelan® and Anaprox®, (naproxen sodium), Lodine® (etodolac), Cataflam® (diclofenac potassium). Voltaren® and Arthrotec®(diclofenac sodium), etc.].
  4. Females who are pregnant, breastfeeding, or are likely to become pregnant.
  5. Subjects with any clinically significant illness within four weeks prior to Period 1 dosing.
  6. Subjects with a positive saliva alcohol test at check-in for any period.
  7. Subjects with a history of alcohol, drug or substance abuse in the past 12 months.
  8. Subjects who have used any prescription medication within 14 days of Period 1 dosing or over-the-counter medication within 14 days of Period 1 dosing.
  9. Subjects deemed uncooperative or noncompliant.
  10. Subjects who have consumed alcohol within 48 hours prior to Period 1 and Period 2 dosing.
  11. Subjects who have consumed xanthine-containing products (including caffeine, theobromines, etc.) within 48 hours prior to Period 1 dosing.
  12. Subjects who have consumed food or beverages containing grapefruit (e.g. fresh, Canned, or frozen) within 14 days prior to the administration of the study medication.
  13. Subjects who have had an abnormal diet within 30 days prior to Period 1 dosing.
  14. Subjects who have participated in an investigational drug study or who have donated more than 100 mL of blood within 30 days prior to Period 1 dosing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01161134

Layout table for location information
Canada, Ontario
Allied Research International Inc.
Mississauga, Ontario, Canada, L4W 1N2
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Layout table for investigator information
Principal Investigator: Deepen M Patel, M.D., C.C.F.P. Allied Research International Inc.
Layout table for additonal information
Responsible Party: Group leader-Research & Development, Dr. Reddy's Laboratories Limited Identifier: NCT01161134    
Other Study ID Numbers: P1CX04001
First Posted: July 13, 2010    Key Record Dates
Last Update Posted: July 13, 2010
Last Verified: August 2004
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action